A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 6 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-07.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 28th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 16th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 185th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2016, is one of 121 in phase 3, and was the 212th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.
This randomized, double-blind, parallel group, placebo-controlled study will evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks for 3 doses on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.
Approximately 38 non-smoking men and women (18 - 65 years of age) corticosteroid-free (oral and inhaled) mild, atopic asthmatics who have demonstrated a dual (early and late) asthmatic response to inhaled allergen challenge at screening will be recruited to complete the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously
Biological: Benralizumab
Placebo administered subcutaneously
Other: Placebo
Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge
To evaluate the effect of benralizumab on allergen-induced increases in eosinophils in induced sputum
Time frame: From prechallenge to 7 hours post allergen challenge during week 9
Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge
To evaluate the effect of benralizumab on the allergen-induced late (3-7 hours post challenge) asthmatic response (LAR)
Time frame: From prechallenge to 3 to 7 hours post allergen challenge during week 9
| Milestone | Benra 30mg q.4 Week | Placebo |
|---|---|---|
| Started | 23 | 23 |
| Completed | 20 | 22 |
| Not completed | 3 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
To evaluate the effect of benralizumab on allergen-induced increases in eosinophils in induced sputum
| Percent | Benra 30mg q.4 Weeks | Placebo |
|---|---|---|
| Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge | 0.822 ± 4.054 | 6.468 ± 9.560 |
To evaluate the effect of benralizumab on the allergen-induced late (3-7 hours post challenge) asthmatic response (LAR)
| Percent | Benra 30mg q.4 Weeks | Placebo |
|---|---|---|
| Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge | 15.152 ± 8.834 | 16.275 ± 10.235 |
Collected over From Visit 1a to Visit 17. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benra 30mg q.4 Week | 0/23 (0%) | 0/23 (0%) | 7/23 (30.4%) |
| Placebo | 0/23 (0%) | 0/23 (0%) | 14/23 (60.9%) |
| Event | Benra 30mg q.4 Week | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 1/23 | 3/23 |
| HeadacheNervous system disorders | 1/23 | 3/23 |
| BronchitisInfections and infestations | 0/23 | 2/23 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/23 | 2/23 |
| CyanosisCardiac disorders | 0/23 | 1/23 |
| VomitingGastrointestinal disorders | 0/23 | 1/23 |
| Catheter site haematomaGeneral disorders | 0/23 | 1/23 |
| Injection site painGeneral disorders | 1/23 | 0/23 |
| MalaiseGeneral disorders | 0/23 | 1/23 |
| Vessel puncture site painGeneral disorders | 0/23 | 1/23 |
| Age, Continuous(Years) | Benra 30mg q.4 Week | Placebo | Total |
|---|---|---|---|
| Mean | 30.4 ± 12.3 | 31.5 ± 13.3 | 30.9 ± 12.7 |
| Age, Customized(Participants) | Benra 30mg q.4 Week | Placebo | Total |
|---|---|---|---|
| >=18 - <=50 | 20 | 20 | 40 |
| >50 - <=65 | 3 | 3 | 6 |
| >65 - <=75 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Benra 30mg q.4 Week | Placebo | Total |
|---|---|---|---|
| Female | 14 | 20 | 34 |
| Male | 9 | 3 | 12 |
| Race/Ethnicity, Customized(Participants) | Benra 30mg q.4 Week | Placebo | Total |
|---|---|---|---|
| White | 16 | 19 | 35 |
| Black or African American | 0 | 0 | 0 |
| Asian | 6 | 3 | 9 |
| Other | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Oct 2019, 36 months.
Results were first posted in Jan 2021, 1 year 2 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 36 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab